Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure (ADRIFT)
Primary Purpose
Atrial Fibrillation, Atrial Appendage, Hemorrhage
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Rivaroxaban 10 mg qd
Rivaroxaban 15 mg qd
DAPT
Sponsored by
About this trial
This is an interventional treatment trial for Atrial Fibrillation focused on measuring Left atrial appendage closure, Rivaroxaban, Dual antiplatelet therapy, Anticoagulation, Stroke prevention
Eligibility Criteria
Inclusion Criteria:
- Men and women ≥18 years of age
- Patients who underwent a clinically successful LAAC procedure (device implanted without procedural or bleeding complication). LAAC may have been indicated for patients contraindicated or unsuitable for long-term Vitamin K antagonists (VKA) anticoagulation.
- AF (permanent or persistent or paroxysmal) patients irrespective of prior antithrombotic treatment are eligible for randomization.
- Written informed consent by the patient or designee if the patient is unable to consent
- Patients affiliated to the French social security system
Exclusion Criteria:
- Creatinine clearance <30 mL / min (Cockcroft formula).
- Dialysis.
- Mechanical heart valves or valvular disease requiring surgery or interventional procedure
- Planned Ablation of AF during follow up period
- Mandatory indication for dual antiplatelet therapy (e.g. recent stent) or single anti-platelet treatment (SAPT) (e.g. high coronary risk).
- Any contra-indication or known allergy to aspirin or clopidogrel or rivaroxaban.
- Any mandatory indication for anticoagulation for a reason other than AF (e.g. Pulmonary embolism)
- Ongoing major bleeding or complicated or recent (<72hours) major surgery
- Known large oesophageal varices or decompensated liver disease (unless a documented positive opinion of a gastro-enterologist)
- Severe thrombocytopenia (<50,000/ml) after referral to haematologist to confirm or not contraindication
- Recent myocardial infarction (<6 weeks).
- Recent cerebro-vascular event (CVE) or transient ischemic attack (<6 weeks) after evaluation of stroke vs bleeding risk by the referring neurologist.
- Recent Intracranial bleeding (< 6 months): these patients will be evaluated by a neurologist as these patients may be considered at higher stroke risk. Neurologist may consider that the LAAC procedure with a short (90 days) period of anticoagulation or antiplatelet therapy as tested in the protocol is a preferable option (in that case intracranial hemorrhage (ICH) will not be considered as a contraindication).
- Prasugrel or ticagrelor concomitant use
- Participating in an investigational drug or another device trial within the previous 30 days.
- High likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical.
- Woman with child bearing potential who do not use an efficient method of contraception.
- positive serum or urine pregnancy test for woman with child bearing potential
- Pregnancy or within 48 hours post-partum or breast feeding women
- Patient under legal protection
Sites / Locations
- Institut de Cardiologie - Hôpital Pitié-Salpêtrière
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
1: Rivaroxaban 10 mg qd
2: Rivaroxaban 15 mg qd
3: DAPT
Arm Description
Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
Outcomes
Primary Outcome Measures
Measure of prothrombin fragment 1 + 2
Measure of prothrombin fragment 1 + 2 at Day 10 (2 to 4 hours after last intake : concentration peak)
Secondary Outcome Measures
Measure of prothrombin fragment 1 + 2
Measure of prothrombin fragment 1 + 2 at Day 90 (2 to 4 hours after last intake : concentration peak)
Factor Xa inhibitory activity at day 10
Factor Xa inhibitory activity
Factor Xa inhibitory activity at day 90
Factor Xa inhibitory activity
Russel Viper venom enzyme assay
Russel Viper venom enzyme assay
TAT complex
TAT complex
TAT complex
TAT complex
D-Dimers
D-Dimersand at peak, 2 to 4 hours after treatment intake
D-Dimers
D-Dimersand at peak, 2 to 4 hours after treatment intake
Prothrombin time (Neoplastin)
Prothrombin time (Neoplastin)
Prothrombin time (Neoplastin)
Prothrombin time (Neoplastin)
Plasma vWf Ag level
plasma vWf Ag level treatment intake
Plasma vWf Ag level
plasma vWf Ag level treatment intake
Haemorrhagic stroke and bleeding will be safety outcomes TEE with central core lab reading: presence of thrombus, peri-device leak
Haemorrhagic stroke and bleeding will be safety outcomes 3-month TEE with central core lab reading: presence of thrombus, peri-device leak
Composite clinical endpoint combining all clinical outcomes
Composite clinical endpoint combining all clinical outcomes : Death, MI, stroke, TIA,
Death (any cause)
Death (any cause) assessed individually and combined at other outcomes
Myocardial infarction (MI)
Myocardial infarction (MI) assessed individually and combined at other outcomes
Stroke (ischaemic stroke, haemorrhagic stroke)
Stroke (ischaemic stroke, haemorrhagic stroke) assessed individually and combined at other outcomes
Transient Ischemic Attack (TIA)
Transient Ischemic Attack (TIA) assessed individually and combined at other outcomes
Systemic embolism
Systemic embolism assessed individually and combined at other outcomes
Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) at day 90
Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) assessed individually and combined at other outcomes
Full Information
NCT ID
NCT03273322
First Posted
August 11, 2017
Last Updated
December 20, 2021
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Action Research Group, Bayer
1. Study Identification
Unique Protocol Identification Number
NCT03273322
Brief Title
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
Acronym
ADRIFT
Official Title
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure: The Randomized ADRIFT Study
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
September 13, 2017 (Actual)
Primary Completion Date
November 20, 2018 (Actual)
Study Completion Date
September 30, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Action Research Group, Bayer
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after left atrial appendage closure. The patients will be assessed at 10 and 90 days: central laboratory hemostasis analysis and clinical events assessment.
Detailed Description
Data on antithrombotic therapy after Left Atrial Appendage Closure (LAAC) are scarce and no randomized evaluation has been performed to demonstrate what is the best antithrombotic strategy following LAAC. LAAC is classically associated with a 6-week period of anticoagulation with warfarin + aspirin followed by once daily clopidogrel (75 mg) + aspirin (81-325 mg) until the 6 months visit, then aspirin alone is continued indefinitely, as tested in patients without contraindication for anticoagulation in the pivotal Watchman trials. LAAC is mostly used in Europe as an alternative to warfarin anticoagulation when patients have a contraindication to or are unsuitable for warfarin anticoagulation. The classic regimen is not applicable and believed to be too risky in such frail patients. These patients usually receive a regimen of daily clopidogrel + aspirin followed by single antiplatelet therapy (most frequently used treatment). Some patients receive oral anticoagulation without aspirin, including NOAC anticoagulation. Rivaroxaban is a tempting strategy for anticoagulation following LAAC in atrial fibrillation (AF) patients. The dose needs first to be carefully evaluated the trial propose a dose ranging study in patients who have undergone successful LAAC.
The study will evaluate two different Rivaroxaban regimen (10 or 15 mg a day) in comparison to dual antiplatelet therapy (DAPT) (aspirin+clopidogrel : control arm representing standard of care) after successful LAAC. The aim is to investigate whether rivaroxaban could provide correct anticoagulation levels and adequately suppress coagulation activation after LAAC.
The patient will be enrolled after left atrial appendage closure before discharge. The randomization is 1/1/1 between the 3 groups : rivaroxaban 10mg a day, rivaroxaban 15 mg a day and aspirin 75mg + clopidogrel 75 mg a day. At 10 and 90 days, the patients will be sampled for biological assessment : Prothrombin fragments 1+2, Factor Xa inhibitory activity, Russel Viper venom enzyme assay, thrombin anti-thrombin (TAT) complex, D-Dimers, Prothrombin time (Neoplastin) and plasma von Willebrand factor (vWf) Ag level
After 90 days, the patient will end his/her participation in the trial. Clinical endpoints (death, MI, Stroke, TIA, systemic embolism, extracranial major bleeding or clinically relevant non major bleeding) at 90 days will be assessed by a clinical endpoint committee. Central echographic laboratory will review all 90 days transesophageal echocardiography (TEE) to detect the presence of thrombus or peri-device leak.
The study is open-label. Central laboratory, clinical endpoint committee and echographic core laboratory is blinded to randomization arm.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Atrial Appendage, Hemorrhage
Keywords
Left atrial appendage closure, Rivaroxaban, Dual antiplatelet therapy, Anticoagulation, Stroke prevention
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
105 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1: Rivaroxaban 10 mg qd
Arm Type
Experimental
Arm Description
Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
Arm Title
2: Rivaroxaban 15 mg qd
Arm Type
Experimental
Arm Description
Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90
should be taken between 8 and 10 AM
Arm Title
3: DAPT
Arm Type
Active Comparator
Arm Description
Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban 10 mg qd
Other Intervention Name(s)
Experimental
Intervention Description
10mg qd
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban 15 mg qd
Other Intervention Name(s)
Experimental
Intervention Description
15mg qd
Intervention Type
Drug
Intervention Name(s)
DAPT
Other Intervention Name(s)
Active comparator
Intervention Description
Aspirin 75 mg qd + Clopidogrel 75 mg qd
Primary Outcome Measure Information:
Title
Measure of prothrombin fragment 1 + 2
Description
Measure of prothrombin fragment 1 + 2 at Day 10 (2 to 4 hours after last intake : concentration peak)
Time Frame
at Day 10
Secondary Outcome Measure Information:
Title
Measure of prothrombin fragment 1 + 2
Description
Measure of prothrombin fragment 1 + 2 at Day 90 (2 to 4 hours after last intake : concentration peak)
Time Frame
at Day 90
Title
Factor Xa inhibitory activity at day 10
Description
Factor Xa inhibitory activity
Time Frame
at Day 10
Title
Factor Xa inhibitory activity at day 90
Description
Factor Xa inhibitory activity
Time Frame
at Day 90
Title
Russel Viper venom enzyme assay
Description
Russel Viper venom enzyme assay
Time Frame
at Day 90
Title
TAT complex
Description
TAT complex
Time Frame
at Day 10
Title
TAT complex
Description
TAT complex
Time Frame
at Day 90
Title
D-Dimers
Description
D-Dimersand at peak, 2 to 4 hours after treatment intake
Time Frame
at Day 10
Title
D-Dimers
Description
D-Dimersand at peak, 2 to 4 hours after treatment intake
Time Frame
at Day 90
Title
Prothrombin time (Neoplastin)
Description
Prothrombin time (Neoplastin)
Time Frame
at Day 10
Title
Prothrombin time (Neoplastin)
Description
Prothrombin time (Neoplastin)
Time Frame
at Day 90
Title
Plasma vWf Ag level
Description
plasma vWf Ag level treatment intake
Time Frame
at Day 10
Title
Plasma vWf Ag level
Description
plasma vWf Ag level treatment intake
Time Frame
at Day 90
Title
Haemorrhagic stroke and bleeding will be safety outcomes TEE with central core lab reading: presence of thrombus, peri-device leak
Description
Haemorrhagic stroke and bleeding will be safety outcomes 3-month TEE with central core lab reading: presence of thrombus, peri-device leak
Time Frame
at Day 90
Title
Composite clinical endpoint combining all clinical outcomes
Description
Composite clinical endpoint combining all clinical outcomes : Death, MI, stroke, TIA,
Time Frame
at Day 90
Title
Death (any cause)
Description
Death (any cause) assessed individually and combined at other outcomes
Time Frame
at Day 90
Title
Myocardial infarction (MI)
Description
Myocardial infarction (MI) assessed individually and combined at other outcomes
Time Frame
at Day 90
Title
Stroke (ischaemic stroke, haemorrhagic stroke)
Description
Stroke (ischaemic stroke, haemorrhagic stroke) assessed individually and combined at other outcomes
Time Frame
at Day 90
Title
Transient Ischemic Attack (TIA)
Description
Transient Ischemic Attack (TIA) assessed individually and combined at other outcomes
Time Frame
at Day 90
Title
Systemic embolism
Description
Systemic embolism assessed individually and combined at other outcomes
Time Frame
at Day 90
Title
Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) at day 90
Description
Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) assessed individually and combined at other outcomes
Time Frame
at Day 90
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women ≥18 years of age
Patients who underwent a clinically successful LAAC procedure (device implanted without procedural or bleeding complication). LAAC may have been indicated for patients contraindicated or unsuitable for long-term Vitamin K antagonists (VKA) anticoagulation.
AF (permanent or persistent or paroxysmal) patients irrespective of prior antithrombotic treatment are eligible for randomization.
Written informed consent by the patient or designee if the patient is unable to consent
Patients affiliated to the French social security system
Exclusion Criteria:
Creatinine clearance <30 mL / min (Cockcroft formula).
Dialysis.
Mechanical heart valves or valvular disease requiring surgery or interventional procedure
Planned Ablation of AF during follow up period
Mandatory indication for dual antiplatelet therapy (e.g. recent stent) or single anti-platelet treatment (SAPT) (e.g. high coronary risk).
Any contra-indication or known allergy to aspirin or clopidogrel or rivaroxaban.
Any mandatory indication for anticoagulation for a reason other than AF (e.g. Pulmonary embolism)
Ongoing major bleeding or complicated or recent (<72hours) major surgery
Known large oesophageal varices or decompensated liver disease (unless a documented positive opinion of a gastro-enterologist)
Severe thrombocytopenia (<50,000/ml) after referral to haematologist to confirm or not contraindication
Recent myocardial infarction (<6 weeks).
Recent cerebro-vascular event (CVE) or transient ischemic attack (<6 weeks) after evaluation of stroke vs bleeding risk by the referring neurologist.
Recent Intracranial bleeding (< 6 months): these patients will be evaluated by a neurologist as these patients may be considered at higher stroke risk. Neurologist may consider that the LAAC procedure with a short (90 days) period of anticoagulation or antiplatelet therapy as tested in the protocol is a preferable option (in that case intracranial hemorrhage (ICH) will not be considered as a contraindication).
Prasugrel or ticagrelor concomitant use
Participating in an investigational drug or another device trial within the previous 30 days.
High likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical.
Woman with child bearing potential who do not use an efficient method of contraception.
positive serum or urine pregnancy test for woman with child bearing potential
Pregnancy or within 48 hours post-partum or breast feeding women
Patient under legal protection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilles MONTALESCOT, MD, PhD
Organizational Affiliation
Centre Hospitalier Universitaire Pitié-Salpêtrière Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut de Cardiologie - Hôpital Pitié-Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32674675
Citation
Duthoit G, Silvain J, Marijon E, Ducrocq G, Lepillier A, Frere C, Dimby SF, Popovic B, Lellouche N, Martin-Toutain I, Spaulding C, Brochet E, Attias D, Mansourati J, Lorgis L, Klug D, Zannad N, Hauguel-Moreau M, Braik N, Deltour S, Ceccaldi A, Wang H, Hammoudi N, Brugier D, Vicaut E, Juliard JM, Montalescot G. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study. Circ Cardiovasc Interv. 2020 Jul;13(7):e008481. doi: 10.1161/CIRCINTERVENTIONS.119.008481. Epub 2020 Jul 17.
Results Reference
derived
Learn more about this trial
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
We'll reach out to this number within 24 hrs